EA007382B1 - Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена - Google Patents

Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена Download PDF

Info

Publication number
EA007382B1
EA007382B1 EA200400695A EA200400695A EA007382B1 EA 007382 B1 EA007382 B1 EA 007382B1 EA 200400695 A EA200400695 A EA 200400695A EA 200400695 A EA200400695 A EA 200400695A EA 007382 B1 EA007382 B1 EA 007382B1
Authority
EA
Eurasian Patent Office
Prior art keywords
mmol
compound
production example
added
dihydro
Prior art date
Application number
EA200400695A
Other languages
English (en)
Russian (ru)
Other versions
EA200400695A1 (ru
Inventor
Джеффри Алан Додж
Венкатеш Гари Кришнан
Чарльз Уиллис Лугар III
Блейк Ли Нойбауэр
Брайан Херст Норман
Ланс Аллен Пфайфер
Тимоти Айво Ричардсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200400695A1 publication Critical patent/EA200400695A1/ru
Publication of EA007382B1 publication Critical patent/EA007382B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
EA200400695A 2001-11-19 2002-11-07 Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена EA007382B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11
PCT/US2002/033622 WO2003044006A1 (en) 2001-11-19 2002-11-07 Substituted benzopyrans as selective estrogen receptor-beta agonists

Publications (2)

Publication Number Publication Date
EA200400695A1 EA200400695A1 (ru) 2004-12-30
EA007382B1 true EA007382B1 (ru) 2006-10-27

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400695A EA007382B1 (ru) 2001-11-19 2002-11-07 Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена

Country Status (23)

Country Link
US (1) US7217734B2 (enExample)
EP (1) EP1448544B1 (enExample)
JP (1) JP4381810B2 (enExample)
KR (1) KR100950616B1 (enExample)
CN (1) CN1312147C (enExample)
AT (1) ATE362471T1 (enExample)
AU (1) AU2002359283B2 (enExample)
CA (1) CA2467013C (enExample)
CY (1) CY1106726T1 (enExample)
DE (1) DE60220179T2 (enExample)
DK (1) DK1448544T3 (enExample)
EA (1) EA007382B1 (enExample)
EC (1) ECSP045113A (enExample)
ES (1) ES2286322T3 (enExample)
HR (1) HRP20040439A2 (enExample)
HU (1) HU229351B1 (enExample)
IL (3) IL161325A0 (enExample)
MX (1) MXPA04004703A (enExample)
NO (1) NO328563B1 (enExample)
NZ (1) NZ531850A (enExample)
PL (1) PL205733B1 (enExample)
PT (1) PT1448544E (enExample)
WO (1) WO2003044006A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1626974B1 (en) * 2003-04-21 2008-08-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
ATE504582T1 (de) * 2004-10-18 2011-04-15 Lilly Co Eli Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
US20060166933A1 (en) * 2004-11-18 2006-07-27 Jain Nareshkumar F Novel 2H-chromene derivatives as selective estrogen receptor modulators
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
CN105960236A (zh) 2013-12-05 2016-09-21 卡罗医药股份公司 用于治疗间皮瘤的雌激素受体β激动剂
JP6978420B2 (ja) 2015-09-17 2021-12-08 オハイオ・ステート・イノヴェーション・ファウンデーション カルボラン化合物及びその使用方法
WO2021183760A1 (en) * 2020-03-11 2021-09-16 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erβ) agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002512A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
WO2001064665A1 (en) * 2000-03-01 2001-09-07 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
EP0935000A3 (en) 1995-09-08 1999-09-08 Karo Bio Ab Orphan receptor
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2003521468A (ja) 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
TR200102992T2 (tr) 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
CA2396059A1 (en) 1999-12-30 2001-07-12 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
ES2293986T3 (es) 2000-03-27 2008-04-01 N.V. Organon Compuestos no esteroides tetraciclicos para tratamientos relacionados con el estrogeno.
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002512A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
WO2001064665A1 (en) * 2000-03-01 2001-09-07 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B.A.M.OUDE-ALINK; A.W.K.CHAN; E.D.GUTSCHE: "Photolysis of 2-keto-2,3-dlhydrobenzofurans, o-hydroxystyrenes and 1-o-hydroxyphenyl)-l,5-hexadienes", JOURNAL OF ORGANIC CHEMISTRY, vol. 38, no. 11, 1973, pages 1993-2001, XP002230195, page 1996, right column, compound 19 *
K.SH. SHRESTHA, K. HONDA, M. ASAMI, S. INOUE: "Facile Synthesis of the Fused 6,6,5 Ring System Containing Chroman Ring from 2-(l-Hydroxy-5-alkenyl)phenol Derivatives via Intramolecular Inverse-Electron-Demand Diels-Alder Reaction", BULL. CHEM. SOC. JAPAN, vol. 72, no. 1, 1999, pages 73-83, XP009005363, page 75, table 2, compounds 14 and 15 in combination with compounds 13a-13d; table 3, compounds 23, 24 in combination with compounds 22a and 22b *
K.W. ANDERSON; J.E. LAVOIE; E.G. LEE: "Synthesis of 6,9-bisnormethyl-8-methoxy-12,13-epoxy-6,8,10-trichothecatriene", JOURNAL OF ORGANIC CHEMISTRY, vol. 42, no. 6, 1977, pages 1045-1050, XP002230194, page 1046, left column, compound 5 *

Also Published As

Publication number Publication date
PL205733B1 (pl) 2010-05-31
NO20042583L (no) 2004-06-18
NO328563B1 (no) 2010-03-22
KR20040063963A (ko) 2004-07-15
US7217734B2 (en) 2007-05-15
HK1068349A1 (en) 2005-04-29
AU2002359283B2 (en) 2007-06-21
MXPA04004703A (es) 2004-08-19
PL374510A1 (en) 2005-10-31
JP4381810B2 (ja) 2009-12-09
DE60220179D1 (de) 2007-06-28
ES2286322T3 (es) 2007-12-01
IL161325A (en) 2008-07-08
IL161325A0 (en) 2004-09-27
HRP20040439A2 (en) 2005-04-30
CN1589268A (zh) 2005-03-02
US20040249167A1 (en) 2004-12-09
EA200400695A1 (ru) 2004-12-30
CY1106726T1 (el) 2012-05-23
IL185867A0 (en) 2008-01-06
KR100950616B1 (ko) 2010-04-01
EP1448544B1 (en) 2007-05-16
AU2002359283A1 (en) 2003-06-10
JP2005513027A (ja) 2005-05-12
NZ531850A (en) 2007-01-26
PT1448544E (pt) 2007-08-10
CN1312147C (zh) 2007-04-25
HUP0402628A2 (hu) 2005-04-28
HU229351B1 (en) 2013-11-28
ECSP045113A (es) 2004-07-23
EP1448544A1 (en) 2004-08-25
CA2467013C (en) 2010-08-10
ATE362471T1 (de) 2007-06-15
CA2467013A1 (en) 2003-05-30
IL185867A (en) 2009-09-22
DE60220179T2 (de) 2008-02-07
WO2003044006A1 (en) 2003-05-30
DK1448544T3 (da) 2007-10-08
AU2002359283B8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
JP3348859B2 (ja) プロテインキナーゼｃインヒビター
KR100487647B1 (ko) 벤조피란함유화합물및이들의사용방법
JP5886873B2 (ja) Ｎ置換アゼチジン誘導体
IL185867A (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US7279499B2 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
KR101823451B1 (ko) 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도
EA001649B1 (ru) Четырехциклические конденсированные соединения с гетероатомами, замещенные арилом, промежуточные соединения, способы получения, композиции и методы лечения
US6630508B1 (en) Substituted benzopyrans as selective estrogen receptor β agonists
EP1805160B1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
EA021536B1 (ru) Производные дитерпеноидов, обладающие биологическими свойствами
AU2015386039B2 (en) Bicyclic pyridine compound
EP1790644A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
HK1068349B (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US20030092695A1 (en) Metal salts of 3-methyl-chromane or thiochromane derivatives
UA77986C2 (en) Substituted benzopyran derivatives as selective estrogen beta-receptor agonists
WO2003074044A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU